GLP-1 Drugs Support-But Do Not Replace-Lifestyle Change, report patients in JAMA study
Researchers have found in a new study that a qualitative study of patient experiences found that GLP-1 receptor agonists (GLP-1 RAs) act as a facilitator rather than a substitute for lifestyle modification. Patients reported that these medications helped them gain greater control over eating behaviors and health habits, but sustained benefits still depended on ongoing diet, exercise, and behavioral changes. The study also highlighted considerable variability in the quality of care and patient support. The authors suggest that standardized guidelines for patient education, clinical follow-up, and behavioral interventions could improve management of expectations, adverse effects, long-term adherence, and overall treatment outcomes. The study was published in JAMA Network Open by Isabella H. and colleagues.
In order to obtain the subtleties of personal experiences of metabolic therapy in modern times, researchers applied a highly structured qualitative protocol involving semistructured video interviews performed during the period from July 22 to September 10, 2025. Researchers gathered a wide array of patients coming from a variety of US states (totally 15 states were represented) using ResearchMatch database as well as snowball sampling techniques.
Individuals who met inclusion criteria in this research included adults who were currently or in the past had been using a GLP-1 RA for various reasons. Hence, it is safe to say that all information provided by participants of the research did not concern only one particular drug or type of patients. For recording purposes, video interviews were used in order to collect in-depth information in verbal format. Once the period of gathering data had ended, the team performed a thorough multi-stage analysis to detect key concepts based on their inductive approach.
Key findings:
- Qualitative research study was conducted to evaluate the detailed experiences of 30 adult participants who hailed from 15 states in the United States, with an average age of 54.0 years and a standard deviation of 8.8 years.
- These participants included 10 who considered themselves men, one who considered themselves non-binary, and 19 who considered themselves women.
- Out of these participants, at the time when the interview was conducted via video, 23 participants were still using GLP-1 RAs, while 7 participants had stopped taking this treatment.
These four main points were covered under the first major area, which included:
(1) A drastic lowering of food noise, mental hunger, or normal appetite;
(2) The common knowledge that GLP-1 RAs cannot be relied on for losing weight alone;
(3) The range of negative effects suffered by the digestive tract; and
(4) The readiness on the part of the patient to endure a lot to achieve their goal of losing weight.
The second category included 4 different themes, namely: (5) a heavy sense of stigma related to the use of GLP-1 RAs, depending largely on whether their principal purpose was the management of diabetes or weight loss; (6) the identification of the importance and variability of information services and medical guidance within clinics; (7) one important challenge, wherein difficulties accessing medications, lack of manufacturing, and expensive cost out-of-pocket were considered entirely prohibitive; and (8) the importance placed on experience sharing.
To summarize, in the present qualitative study of patients' experiences of GLP-1 receptor agonists, it became clear that GLP-1 RA treatment served as an enabler, not a substitute for changes in behavior, underscoring the importance of interventions on both psychological and pharmacological levels for successful treatment. The quality of healthcare delivery was highly inconsistent; therefore, the establishment of standardized guidelines would be beneficial in managing patients' expectations concerning side effects.
Reference:
de Vere Hunt I, Ramirez-Posada M, Babu CS, Brown-Johnson C, Linos E, Rodriguez F. Patient Experiences With GLP-1 Receptor Agonists. JAMA Netw Open. 2026;9(6):e2616951. doi:10.1001/jamanetworkopen.2026.16951
